title: Current management of corticosteroid-induced osteoporosis: variations in awareness and management.
abstract: BACKGROUND
  Guidelines for the prevention of corticosteroid-induced osteoporosis (CIO) have been widely published. There are no guidelines on the use of gastro-protectants with corticosteroids (CS).
  
  
  OBJECTIVE
  To determine whether patients receiving CS therapy are evaluated and treated for osteoporosis risk, how management varied by steroid dose and diagnosis, and how many patients received gastro-protection.
  
  
  METHODS
  A retrospective audit of 4,350 patients presenting to four medical specialities.
  
  
  RESULTS
  One hundred and fifty-one patients prescribed CS were identified. Indications for CS therapy included renal transplantation (32%) and asthma/respiratory diseases (23%), inflammatory arthritis/vasculitis (32%) and inflammatory bowel disease/auto-immune hepatitis/other (13%). Risk of osteoporosis was mentioned in 13% of charts. The prescription rates for bone protection agents varied from 69% to 4% according to the medical speciality attended. Gastro-protectants were prescribed for 44% of patients.
  
  
  CONCLUSIONS
  There are large variations among medical specialties both in the prescription of gastro-protectant agents and in the use of measures to prevent CIO. Simpler guidelines could facilitate rational prescribing in these patients.
authors.affiliation: Department of Rheumatology, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland.
authors.forename: J G
authors.initials: JG
authors.lastname: Ryan
authors.forename: R K
authors.initials: RK
authors.lastname: Morgan
authors.forename: P J
authors.initials: PJ
authors.lastname: Lavin
authors.forename: F E
authors.initials: FE
authors.lastname: Murray
authors.forename: P G
authors.initials: PG
authors.lastname: O'Connell
mesh_terms: D000305:Adrenal Cortex Hormones / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000139:chemically induced* / Q000188:drug therapy; D012189:Retrospective Studies
chemical_list: D000305:Adrenal Cortex Hormones
references.citation: Rheumatology (Oxford). 1999 Mar;38(3):198-201
references.pmid: 10325657
references.citation: J R Coll Physicians Lond. 1997 Mar-Apr;31(2):158-61
references.pmid: 9131514
references.citation: BMJ. 1996 Aug 10;313(7053):344-6
references.pmid: 8760745
references.citation: JAMA. 2002 Jul 17;288(3):321-33
references.pmid: 12117397
references.citation: Ann Rheum Dis. 2002 Jan;61(1):32-6
references.pmid: 11779755
references.citation: N Engl J Med. 1983 Jul 7;309(1):21-4
references.pmid: 6343871
references.citation: Ann Pharmacother. 1996 Jul-Aug;30(7-8):870-2
references.pmid: 8826575
references.citation: Chest. 1999 Dec;116(6):1733-49
references.pmid: 10593801
references.citation: Gut. 2000 Jan;46 Suppl 1:i1-8
references.pmid: 10647595
references.citation: Postgrad Med J. 2002 Apr;78(918):242-3
references.pmid: 11930029
references.citation: Arthritis Rheum. 2002 Dec;46(12):3136-42
references.pmid: 12483716
references.citation: Br J Rheumatol. 1997 Oct;36(10):1035-7
references.pmid: 9374917
references.citation: QJM. 2000 Feb;93(2):105-11
references.pmid: 10700481
references.citation: Arthritis Rheum. 2001 Jul;44(7):1496-503
references.pmid: 11465699